CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. Chief Technology Officer Raymond Woo exercised options on October 1, 2026, to acquire 4,864 shares at $3.65 per share and 23 shares at $4.70 per share, and sold 4,887 shares at $24.38 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan Raymond Woo adopted on June 5, 2026.
Ceribell, Inc. officer Raymond Woo listed 4,887 common shares for sale through Fidelity Brokerage Services LLC, with an approximate aggregate market value of $119,145.06 and a sale date of October 1, 2026. An October 1 stock-option exercise for 4,887 shares, with cash payment, is also listed.
For the preceding three months, Woo listed sales of 1,979 shares for $47,539.14 on August 21, 2026, and 4,887 shares for $118,900.71 on September 8, 2026.
Ceribell, Inc. (CBLL) director, President and CEO Chao Xingjuan reported selling 20,846 shares of common stock on September 15, 2026 at a weighted average price of $25.03 per share under a Rule 10b5-1 trading plan adopted September 12, 2025. Following this sale, she holds 746,345 shares directly and 369,088 shares indirectly through the ACP 2021 Trust, for which she is a co-trustee and disclaims beneficial ownership except for her pecuniary interest.
Ceribell, Inc. (CBLL) reported that its Chief Financial Officer, Scott Blumberg, exercised stock options for 846 shares of common stock at an exercise price of $9.41 per share on September 15, 2026, and sold 846 shares of common stock at a weighted average price of about $25 per share the same day. These transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following the option exercise, he held 51,802 stock options that are fully vested and currently exercisable.
Ceribell, Inc. (CBLL) received a notice under Rule 144 that officer Scott E. Blumberg, through Fidelity Brokerage Services LLC, intends to sell 846 shares of Ceribell common stock, with an aggregate market value of $21,150.81, around September 15, 2026 on NASDAQ.
The notice states that 38,378,101 shares of Ceribell common stock were outstanding. The shares to be sold are tied to a stock options exercise for cash. The filing also lists prior sales by Scott E. Blumberg over the past three months.
Ceribell, Inc. (CBLL) disclosed that shareholder Xingjuan Chao has filed a Form 144 indicating an intention to sell up to 20,846 shares of common stock, acquired through a stock option exercise dated April 30, 2018. The filing lists Fidelity Brokerage Services LLC as the broker and references Ceribell common stock listed on NASDAQ.
The notice also reports prior open-market sales of Ceribell common stock by Xingjuan Chao over the past three months, providing share amounts and total proceeds for each transaction.
Ceribell, Inc. insider David Foehr, Senior VP, Finance and PAO, exercised options for 7,500 shares of common stock at $4.70 per share on September 8, 2026, and on the same date sold a total of 9,255 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
After the option exercise, he reported 45,385 option-based rights remaining; his common-stock holdings after the sales were not stated.
Ceribell, Inc. (CBLL) reported that Chief Technology Officer Raymond Woo exercised stock options to acquire a total of 13,276 shares of common stock on September 8, 2026, at exercise prices of $2.24, $3.65, and $4.70 per share, and sold 4,887 shares of common stock at $24.33 per share the same day. The company states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Woo on June 5, 2026.
Ceribell, Inc. (CBLL) has a notice under Rule 144 filed on behalf of officer David J. Foehr for a planned sale of 9,255 shares of common stock through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $225,174.15, on or about September 8, 2026 on NASDAQ.
The shares to be sold are tied to restricted stock vesting events of 879 shares on May 20, 2026 and 876 shares on August 20, 2026, and a stock option exercise for 7,500 shares on September 8, 2026. The notice also lists prior open-market sales by Foehr during the past three months.
Ceribell, Inc. (CBLL) is the issuer of common stock subject to a proposed resale under Rule 144 by Raymond Woo. A notice lists 4,887 shares of common stock held at Fidelity Brokerage Services LLC, with an aggregate market value of $118,900.71 as of September 8, 2026, to be sold on NASDAQ following a stock option exercise for cash. The notice also reports that Woo sold 1,979 shares of Ceribell common stock during the prior three months for $47,539.14. The filing is signed by Daniel Tucci as a duly authorized representative of Fidelity, acting as attorney-in-fact for Raymond Woo.